Phases, active trials: Phase 1: 20, Phase 1/2: 8, Phase 2: 26, Phase 2/3: 7, Phase 3: 26, Phase 4: 2, No phase listed: 2
Gilead Sciences has evolved from a virology-focused company into a diversified biopharmaceutical with major oncology and liver disease programs. Their hematology-oncology franchise centers on CAR-T therapies, Yescarta (axicabtagene ciloleucel) for large B-cell lymphoma and follicular lymphoma, and Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma and B-cell ALL. Through the acquisition of Immunomedics, Gilead gained Trodelvy (sacituzumab govitecan), a TROP2-targeting ADC approved in triple-negative breast cancer and urothelial cancer, with an active expansion program in HR+ breast cancer, NSCLC, and other solid tumors. In liver disease, Gilead's NASH/MASH pipeline includes seladelpar (PPARδ), cilofexor, and firsocostat across multiple combination trials. Their HIV franchise, anchored by Biktarvy and the lenacapavir long-acting program, continues generating registrations for pre-exposure prophylaxis and treatment extensions.
- Hematology / oncology (CAR-T, ADC)
- Solid tumors (TROP2, TROP2 combos)
- HIV (long-acting, PrEP, treatment)
- Liver disease (NASH/MASH, HCV/HBV)
- Inflammation (filgotinib, JAK1)
- Yescarta (axicabtagene ciloleucel): CD19 CAR-T, LBCL/FL
- Trodelvy (sacituzumab govitecan): TROP2 ADC, TNBC/urothelial
- Tecartus (brexucabtagene autoleucel): CD19 CAR-T, MCL/B-ALL
- Lenacapavir: HIV capsid inhibitor, long-acting
- Seladelpar: PPARδ agonist, MASH/PBC
- Magrolimab: CD47 antibody, myeloid malignancies
A primary completion date pushed out, enrollment cut, or a primary endpoint changed in the last 90 days. Active trials only.
| Trial | Warning signs | Status |
|---|---|---|
| Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma… NCT06626919 | Primary completion moved at least 1 year 6 months later Primary endpoint(s) modified | Recruiting |
14 more on the Trials at Risk page. See which trials →
Phase 2 and Phase 3 trials with a primary completion date in the next 180 days, as ClinicalTrials.gov estimates it today. Active trials only.
| Trial | Scheduled | Phase |
|---|---|---|
| Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast… NCT04639986 | Dec 2026 · Estimated | Phase 3 |
7 more on the Completions page. See the calendar →
Monitor the Gilead Sciences pipeline daily
Get a daily digest when Gilead Sciences registers new trials or updates existing protocols. Free plan, no credit card required.
Start monitoring free| Condition / indication | Active trials |
|---|---|
| HIV-1-infection | 11 |
| HIV-1 Infection | 5 |
| Pre-Exposure Prophylaxis of HIV Infection | 5 |
| Advanced Solid Tumors | 4 |
| Triple Negative Breast Cancer | 4 |
| Advanced Solid Tumor | 3 |
| HIV Infections | 3 |
| Non-small Cell Lung Cancer | 3 |
Gilead's Trodelvy (sacituzumab govitecan) expansion trials, into HR+ breast cancer, NSCLC, and endometrial cancer, are among the most competitive in the TROP2 ADC space, directly competing with AstraZeneca's Dato-DXd. Their lenacapavir long-acting HIV program is closely tracked for its pre-exposure prophylaxis indication registrations.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Gilead Sciences's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.
- Sponsor normalization: Gilead Sciences may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Gilead Sciences pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Get started free| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| Study of GS-2426 in Participants With Advanced Solid Tumors NCT07601243 | Recruiting | Trial sites expanded: 4 → 8 locations | 2026-11-13 |
| Study of GS-0201 Alone and in Combination in Participants With Advanced Solid… NCT06167317 | Recruiting | Trial sites expanded: 8 → 14 locations | 2026-11-13 |
| Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy… NCT07708727 | Recruiting | Trial sites expanded: 16 → 21 locations | 2026-11-11 |
| A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in… NCT07645287 | Recruiting | Trial sites expanded: 55 → 59 locations | 2026-11-11 |
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in… NCT07546812 | Active, Not Recruiting | Enrollment closed, study ongoing | 2026-11-11 |
Each trial page shows every change DataLookout has recorded for that trial.